<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092104</url>
  </required_header>
  <id_info>
    <org_study_id>652-2-201</org_study_id>
    <nct_id>NCT01092104</nct_id>
  </id_info>
  <brief_title>A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients</brief_title>
  <official_title>A Proof of Concept, Multiple Dose-Escalating Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tobira Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tobira Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized, placebo-controlled, dose-escalating study to assess the antiviral&#xD;
      activity, safety, tolerability, and pharmacokinetics (PK) of the CCR5 antagonist TBR 652&#xD;
      monotherapy dosed orally once daily (QD) for 10 days in HIV 1-infected, antiretroviral&#xD;
      treatment-experienced, CCR5 antagonist-naïve patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-1 RNA Change from Baseline</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>TBR-652 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBR 25 mg QD for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo QD for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBR-652 50 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBR-652 50 mg QD for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBR-652 75 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBR-652 75 mg QD for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBR-652 100 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBR-652 100 mg QD for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBR-652 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBR-652 150 mg QD for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652</intervention_name>
    <description>TBR-652 25 mg</description>
    <arm_group_label>TBR-652 25 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652 Matching Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652 50 mg</intervention_name>
    <description>TBR-652 50 mg QD for 10 days</description>
    <arm_group_label>TBR-652 50 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652 75 mg</intervention_name>
    <description>TBR-652 75 mg QD for 10 days</description>
    <arm_group_label>TBR-652 75 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652 100 mg</intervention_name>
    <description>TBR-652 100 mg QD for 10 days</description>
    <arm_group_label>TBR-652 100 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652 150 mg</intervention_name>
    <description>TBR-652 150 mg QD for 10 days</description>
    <arm_group_label>TBR-652 150 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. No clinically significant findings on Screening evaluations (clinical, laboratory, and&#xD;
             ECG), which in the opinion of the Investigator would interfere with the subject's&#xD;
             ability to comply with the protocol.&#xD;
&#xD;
          2. Antiretroviral treatment-experienced; no antiretroviral therapy for at least 6 weeks&#xD;
             prior to study entry.&#xD;
&#xD;
          3. CCR5 antagonist therapy naive.&#xD;
&#xD;
          4. CD4 cell count &gt;/= 250 cells/mm3 during Screening (within 30 days prior to first&#xD;
             dose).&#xD;
&#xD;
          5. Two separate qualifying plasma HIV 1 RNA levels &gt;/= 5,000 copies/mL within 45 days&#xD;
             prior to first dose.&#xD;
&#xD;
          6. Females who are not of reproductive potential (documented to be surgically sterile or&#xD;
             postmenopausal [defined as amenorrhea ≥ 1 year and follicle stimulating hormone {FSH}&#xD;
             ≥ 30 mU/mL]).&#xD;
&#xD;
          7. Females of child-bearing potential may be enrolled following a negative serum&#xD;
             pregnancy test. If participating in activity that could lead to pregnancy, males and&#xD;
             females shall agree to use two forms of barrier method contraception during the trial&#xD;
             and for 2 months after stopping the medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of CXCR4- or dual/mixed-tropic HIV 1 virus.&#xD;
&#xD;
          2. Active CDC category C disease (except cutaneous Kaposi's sarcoma not requiring&#xD;
             systemic therapy during the trial).&#xD;
&#xD;
          3. History of infection with hepatitis B or hepatitis C virus, history of cirrhosis, or&#xD;
             any known active or chronic liver disease. NOTE: Hepatitis B vaccinated patients are&#xD;
             eligible.&#xD;
&#xD;
          4. Serum ALT or AST values greater than Grade 1 or bilirubin values greater than the&#xD;
             upper limit of normal (ULN) at Screening.&#xD;
&#xD;
          5. History of HIV-2.&#xD;
&#xD;
          6. Recent history (&lt; 30 days prior to study drug administration) of clinically&#xD;
             significant infection.&#xD;
&#xD;
          7. Pregnant females or females who are breastfeeding.&#xD;
&#xD;
          8. Treatment with immunomodulating agents (such as systemic corticosteroids,&#xD;
             interleukins, interferons) or any agent with known anti-HIV activity within 30 days&#xD;
             prior to study drug administration.&#xD;
&#xD;
          9. Treatment with any vaccine within 30 days of study drug administration.&#xD;
&#xD;
         10. A positive pre-study drug screen, including amphetamines, barbiturates, cocaine, or&#xD;
             PCP.&#xD;
&#xD;
         11. Anticipated use of antacids during the trial and/or within 7 days prior to first dose&#xD;
             of study drug.&#xD;
&#xD;
         12. Current alcohol or drug use, which in the expert judgment of the investigator, will&#xD;
             interfere with the patient's ability to comply with the protocol requirements.&#xD;
&#xD;
         13. Inability, in the opinion of the investigator, to comply with the dosing schedule and&#xD;
             protocol evaluations.&#xD;
&#xD;
         14. Use of any experimental medications within 4 weeks prior to Screening.&#xD;
&#xD;
         15. Current (within 30 days prior to the first dose of study drug) or anticipated use of&#xD;
             antimetabolites; alkylating agents; or drugs, herbal preparations, and foods&#xD;
             (including grapefruit) known to affect the CYP 3A4 or CYP 2C8 enzymes or&#xD;
             P-glycoprotein transporters.&#xD;
&#xD;
         16. History of clinically significant hepatic, metabolic, endocrine, renal, hematologic,&#xD;
             pulmonary, gastrointestinal, or cardiovascular disorders (including ECG&#xD;
             abnormalities).&#xD;
&#xD;
         17. Uncontrolled hypertension.&#xD;
&#xD;
         18. Presence of a malabsorption syndrome affecting drug absorption (e.g., Crohn's disease,&#xD;
             chronic pancreatitis).&#xD;
&#xD;
         19. History of malignancy with exception of cured basal or squamous cell carcinoma of the&#xD;
             skin.&#xD;
&#xD;
         20. Receipt of radiation or cytotoxic chemotherapeutic agents and not recovered from side&#xD;
             effects prior to the first dose of study medication.&#xD;
&#xD;
         21. Subjects who have used any over-the-counter medications (including phytotherapeutic,&#xD;
             herbal, or plant-derived preparations) within 14 days prior to the first dose of study&#xD;
             medication, unless approved by the Investigator, or who have used St. John's wort&#xD;
             within 21 days prior to the first dose of study drug. (St. John's wort is prohibited&#xD;
             during the study.)&#xD;
&#xD;
         22. History or presence of an abnormal ECG.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Lalezari J, Gathe J, Brinson C, Thompson M, Cohen C, Dejesus E, Galindez J, Ernst JA, Martin DE, Palleja SM. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25. doi: 10.1097/QAI.0b013e318213c2c0.</citation>
    <PMID>21317794</PMID>
  </results_reference>
  <results_reference>
    <citation>Marier JF, Trinh M, Pheng LH, Palleja SM, Martin DE. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients. Antimicrob Agents Chemother. 2011 Jun;55(6):2768-74. doi: 10.1128/AAC.00713-10. Epub 2011 Apr 12.</citation>
    <PMID>21486960</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>March 22, 2010</study_first_submitted>
  <study_first_submitted_qc>March 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <disposition_first_submitted>June 19, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 3, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 10, 2013</disposition_first_posted>
  <last_update_submitted>July 3, 2013</last_update_submitted>
  <last_update_submitted_qc>July 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cenicriviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

